What Are SGLT2 Inhibitors?

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of oral glucose-lowering medications introduced in the early 2010s. They target the SGLT2 protein in the proximal renal tubule, which is responsible for reabsorbing approximately 90% of filtered glucose back into the bloodstream. By blocking this transporter, SGLT2 inhibitors cause glycosuria — the excretion of glucose in urine — thereby lowering plasma glucose levels independent of insulin secretion or action.

Commonly prescribed SGLT2 inhibitors include:

  • Canagliflozin (Invokana)
  • Dapagliflozin (Farxiga)
  • Empagliflozin (Jardiance)
  • Ertugliflozin (Steglatro)

These agents are typically used as second- or third-line therapy in type 2 diabetes, often in combination with metformin, but they have also gained prominent roles in heart failure and chronic kidney disease management irrespective of diabetes status. Their glucose-lowering efficacy is modest — lowering HbA1c by 0.5–1.0% — but their pleiotropic benefits extend well beyond glycemic control.

Mechanism of Action: How SGLT2 Inhibitors Differ

The fundamental distinction between SGLT2 inhibitors and other diabetes drugs lies in their mechanism. SGLT2 inhibitors remove glucose through the urine, an insulin-independent pathway. This contrasts sharply with other major classes:

  • Metformin primarily reduces hepatic gluconeogenesis and improves insulin sensitivity in peripheral tissues.
  • Insulin directly replaces or supplements endogenous insulin, facilitating glucose uptake into cells.
  • Sulfonylureas and meglitinides stimulate pancreatic beta cells to secrete more insulin.
  • GLP-1 receptor agonists enhance glucose-dependent insulin secretion, slow gastric emptying, and suppress glucagon.
  • DPP-4 inhibitors prolong the action of endogenous incretins, leading to modest increases in insulin and decreases in glucagon.
  • Thiazolidinediones (TZDs) improve insulin sensitivity primarily in adipose tissue.

Because SGLT2 inhibitors do not rely on insulin secretion, they carry a low intrinsic risk of hypoglycemia when used alone. This makes them attractive for patients who are prone to hypoglycemic events with sulfonylureas or insulin.

Cardiovascular and Renal Benefits

Perhaps the most paradigm-shifting difference between SGLT2 inhibitors and older diabetes medications is their proven cardiovascular and renal protective effects. Large cardiovascular outcome trials (e.g., EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58) have demonstrated significant reductions in:

  • Major adverse cardiovascular events (MACE) — especially in patients with established atherosclerotic cardiovascular disease.
  • Hospitalization for heart failure.
  • Progression of chronic kidney disease (CKD) and end-stage renal disease.

These benefits appear to be independent of glycemic control and are now reflected in clinical practice guidelines. For example, the American Diabetes Association recommends SGLT2 inhibitors for patients with type 2 diabetes and established heart failure or CKD. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines similarly endorse their use in CKD with albuminuria.

No other oral diabetes medication class, except GLP-1 receptor agonists, has replicated this magnitude of cardiorenal benefit in large trials. Metformin, while safe and effective for glycemic control, does not demonstrate the same heart failure or renal outcome improvements.

Weight and Metabolic Effects

SGLT2 inhibitors consistently produce modest weight loss — typically 2–4 kg over 6–12 months — due to caloric loss from glycosuria. This is a meaningful advantage for many patients with type 2 diabetes who are overweight or obese. In contrast, insulin, sulfonylureas, and TZDs are associated with weight gain. Metformin is weight-neutral or associated with slight weight loss. GLP-1 agonists also promote weight loss, often similar to or greater than SGLT2 inhibitors.

Blood Pressure Effects

Through osmotic diuresis and mild natriuresis, SGLT2 inhibitors lower systolic blood pressure by 3–5 mm Hg. This contributes to cardiovascular risk reduction. Other diabetes medications have variable effects: metformin is neutral; insulin can lower blood pressure if glycemic improvement reduces sympathetic activity but may increase it if weight gain occurs; sulfonylureas and DPP-4 inhibitors are generally blood-pressure-neutral.

Side Effect Profile and Risk Considerations

The side effect profile of SGLT2 inhibitors differs substantially from other classes.

SGLT2 Inhibitor-Specific Risks

  • Genitourinary infections: Increased risk of genital mycotic infections (e.g., balanitis, vulvovaginitis) due to glucosuria. Urinary tract infections are also slightly more common.
  • Dehydration and hypotension: Volume depletion from osmotic diuresis can cause dizziness, orthostasis, and hypotension, especially in elderly patients or those on diuretics.
  • Diabetic ketoacidosis (DKA): A rare but serious risk — euglycemic DKA can occur even with near-normal blood glucose levels. It is more common in type 1 diabetes and should prompt caution in off-label use.
  • Acute kidney injury: Although SGLT2 inhibitors are renoprotective long-term, acute kidney injury can occur in the setting of volume depletion or concomitant nephrotoxic drugs.
  • Fournier gangrene: A very rare but life-threatening necrotizing infection of the perineum, with increased risk in males.

Risks of Other Common Diabetes Drugs

  • Metformin: Gastrointestinal intolerance, lactic acidosis (very rare), vitamin B12 deficiency with long-term use.
  • Sulfonylureas: Hypoglycemia, weight gain, and potential for cardiovascular harm (some older agents).
  • Insulin: Hypoglycemia, weight gain, injection-site reactions.
  • GLP-1 receptor agonists: Nausea, vomiting, diarrhea; rare pancreatitis; possible risk of medullary thyroid carcinoma (C-cell tumors).
  • TZDs: Fluid retention, weight gain, increased fracture risk in women, potential heart failure exacerbation (rosiglitazone).
  • DPP-4 inhibitors: Generally well tolerated; rare pancreatitis; possible joint pain.

Clinical Decision-Making: When to Choose SGLT2 Inhibitors

Given the unique profile of SGLT2 inhibitors, they are not always first-line but are increasingly preferred in specific patient populations. The latest treatment algorithms emphasize a patient-centered approach. Key considerations include:

Patient with Established Cardiovascular Disease

For patients with type 2 diabetes and atherosclerotic CVD, an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit is recommended after metformin. Empagliflozin and dapagliflozin have strong evidence for reducing MACE and heart failure hospitalizations.

Patient with Heart Failure

In patients with heart failure with reduced ejection fraction (HFrEF), SGLT2 inhibitors are now part of the standard quadruple therapy, regardless of diabetes status. Dapagliflozin and empagliflozin have shown reductions in heart failure hospitalizations and cardiovascular death.

Patient with Chronic Kidney Disease

For patients with CKD (eGFR 25–90 mL/min/1.73 m²) and albuminuria, SGLT2 inhibitors slow progression of kidney disease. Canagliflozin, dapagliflozin, and empagliflozin have all demonstrated renal benefits. Note that SGLT2 inhibitor efficacy declines when eGFR falls below 30–45 mL/min/1.73 m², and they are generally not initiated below that threshold.

Patient at Risk for Hypoglycemia

Patients with frequent hypoglycemia or fear of hypoglycemia may benefit from SGLT2 inhibitors due to their low hypoglycemic potential when used without insulin or sulfonylureas. Metformin also has low risk; GLP-1 agonists and DPP-4 inhibitors have low risk. Conversely, sulfonylureas and insulin carry higher risk.

Patient Struggling with Weight

SGLT2 inhibitors and GLP-1 agonists are both weight-loss-friendly, while sulfonylureas, TZDs, and insulin can cause weight gain. If weight loss is a priority, SGLT2 inhibitors are a reasonable choice, especially in combination with metformin.

Combination Therapy: SGLT2 Inhibitors with Other Agents

SGLT2 inhibitors are often used as part of multidrug regimens. They complement metformin well because of differing mechanisms. Combination with GLP-1 receptor agonists is particularly attractive: the GLP-1 agonist improves insulin secretion and slows gastric emptying, while the SGLT2 inhibitor provides glucose excretion and cardiorenal benefits. The combination may produce additive HbA1c reduction and weight loss.

However, caution is warranted when using SGLT2 inhibitors with insulin or sulfonylureas because of the increased risk of hypoglycemia. In such cases, dose reduction of insulin or sulfonylurea may be necessary.

Contraindications and Cautions

SGLT2 inhibitors are contraindicated in:

  • Type 1 diabetes (though some off-label use occurs with extreme caution).
  • Severe renal impairment (eGFR < 30 mL/min/1.73 m² for initiation).
  • History of diabetic ketoacidosis.
  • Hypersensitivity to any component.

Caution is needed in patients using loop diuretics, those with low baseline systolic blood pressure (< 95 mm Hg), elderly patients, and those at risk of volume depletion. Temporary discontinuation before surgery or during acute illness is recommended.

Cost and Access Considerations

Brand-name SGLT2 inhibitors are generally more expensive than generic metformin or sulfonylureas. However, insurance coverage and patient assistance programs have improved. In many countries, empagliflozin and dapagliflozin are now available as generics or at lower cost. Cost-effectiveness analyses support their use in patients with CVD or CKD because of reduced hospitalizations. Patients should discuss financial options with their healthcare provider.

Future Directions

Research continues to explore the mechanisms behind the remarkable benefits of SGLT2 inhibitors. Emerging evidence suggests effects on myocardial energetics, inflammation, and fibrosis. The expanding indications — including for heart failure with preserved ejection fraction and in non-diabetic CKD — underscore that these drugs represent a therapeutic shift beyond diabetes.

Summary: Key Differences at a Glance

  • Mechanism: SGLT2 inhibitors cause glycosuria; other drugs act via insulin secretion, sensitivity, or hepatic glucose output.
  • Cardiovascular: SGLT2 inhibitors reduce MACE and heart failure hospitalizations; metformin is neutral; sulfonylureas may increase risk.
  • Renal: SGLT2 inhibitors slow CKD progression; others generally lack or have neutral renal effects except for metformin caution at low eGFR.
  • Weight: SGLT2 inhibitors promote weight loss; GLP-1 agonists also promote loss; insulin/sulfonylureas/TZDs cause gain.
  • Hypoglycemia risk: Low with SGLT2 inhibitors (if used without insulin); low with metformin/DPP-4; high with sulfonylureas/insulin.
  • Side effects: Unique UTI/genital infections, euglycemic DKA with SGLT2 inhibitors; other classes have distinct profiles.

Understanding these differences empowers patients and clinicians to make informed, personalized medication choices that optimize diabetes management and reduce long-term complications.